Paragon Agreements - Additional Information (Details) |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Apr. 30, 2026
USD ($)
|
Oct. 31, 2025
USD ($)
|
Sep. 30, 2025
USD ($)
Employee
Vote
|
Sep. 30, 2026
USD ($)
|
Sep. 30, 2025
USD ($)
|
Sep. 30, 2026
USD ($)
|
Sep. 30, 2025
USD ($)
|
Dec. 31, 2026 |
Dec. 31, 2025
USD ($)
|
Mar. 19, 2026
USD ($)
|
|||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| License agreement expiration terms | Unless terminated earlier, the Paragon ADOA shall continue in force on a Research Program-by-Research Program basis until the later of: (i) the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii) if the Company exercises its Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 30 days, the expiration of such 30-day period (subject to any mutually agreed extension of such period); and (iii) the expiration of the applicable Research Term (as defined under the Paragon ADOA). The Company may terminate the Paragon ADOA or any Research Program at any time for any or no reason upon 30 days’ prior written notice to Paragon, provided that the Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Paragon ADOA or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Paragon ADOA or any Research Program upon (i) 30 days’ prior written notice of the other party’s material breach that remains uncured for the 30-day period and (ii) the other party’s bankruptcy. | |||||||||||
| Research and development | [1] | $ 42,139 | $ 20,479 | $ 69,130 | $ 20,732 | |||||||
| Share-based compensation expense | 17,420,000 | 245,000 | ||||||||||
| Warrant liability, related party | 13,508,000 | 13,508,000 | $ 0 | |||||||||
| Paragon Antibody Discovery and Option Agreement | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Percentage of milestone payment reduction | 50.00% | |||||||||||
| Milestone payment | $ 5,000,000 | |||||||||||
| Collaborative arrangement, payment for one time fee | $ 1,000,000 | |||||||||||
| Warrant coverage percentage | 1.00% | 1.00% | ||||||||||
| Paragon Antibody Discovery and Option Agreement | Maximum | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Non-refundable milestone payments | $ 46,000,000 | $ 46,000,000 | $ 46,000,000 | |||||||||
| Paragon Platform Option Agreement | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Percentage of milestone payment reduction | 50.00% | |||||||||||
| Arrangements recorded expense | 1,400,000 | 1,400,000 | ||||||||||
| License option exercise fee | $ 5,000,000 | |||||||||||
| Options exercised | 0 | 0 | ||||||||||
| Option exercise fee | 2,000,000 | |||||||||||
| Paragon Platform Option Agreement | Related Party | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Unpaid expense | 1,400,000 | 1,400,000 | ||||||||||
| Paragon Platform Option Agreement | Maximum | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Non-refundable milestone payments | $ 41,000,000 | |||||||||||
| Paragon Antibody Oligo Conjugate Research Letter Agreement | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Arrangements recorded expense | 2,000,000 | 3,000,000 | ||||||||||
| Research and development | 2,000,000 | 3,000,000 | ||||||||||
| Research initiation fees | $ 1,000,000 | |||||||||||
| Upfront license fee | $ 5,000,000 | |||||||||||
| Paragon Antibody Oligo Conjugate Research Letter Agreement | Related Party | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Unpaid expense | 2,000,000 | 2,000,000 | ||||||||||
| Korsana | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Number of employees in joint development committee | Employee | 2 | |||||||||||
| Korsana | Related Party | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Unpaid expense | 7,600,000 | 7,600,000 | $ 10,600,000 | |||||||||
| Paragon | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Number of employees in joint development committee | Employee | 2 | |||||||||||
| Paragon ADOA | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Number of votes per each employee | Vote | 1 | |||||||||||
| Arrangements recorded expense | 20,300,000 | 35,500,000 | ||||||||||
| Research and development | 7,600,000 | 16,000,000 | ||||||||||
| Development milestone payment | 5,000,000 | |||||||||||
| Research initiation milestone | 1,000,000 | |||||||||||
| 2026 Parasa Warrant Obligation | ||||||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||
| Share-based compensation expense | 12,700,000 | 13,500,000 | ||||||||||
| Warrant liability, related party | $ 13,500,000 | $ 13,500,000 | ||||||||||
| ||||||||||||